Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure

被引:9
|
作者
Narita, Atsuya [1 ,2 ]
Takeda, Atsuya [3 ]
Eriguchi, Takahisa [3 ]
Saigusa, Yusuke [4 ]
Sanuki, Naoko [3 ]
Tsurugai, Yuichiro [3 ]
Enomoto, Tatsuji [2 ]
Kuribayashi, Hidehiko [2 ]
Mizuno, Tomikazu [5 ]
Yashiro, Kae [5 ]
Hara, Yu [1 ]
Kaneko, Takeshi [1 ]
机构
[1] Yokohama City Univ, Dept Pulmonol, Grad Sch Med, Yokohama, Kanagawa, Japan
[2] Ofuna Chuo Hosp, Dept Resp Med, Kamakura, Kanagawa, Japan
[3] Ofuna Chuo Hosp, Radiat Oncol Ctr, 6-2-24 Ofuna, Kamakura, Kanagawa 2470056, Japan
[4] Yokohama City Univ, Dept Biostat, Sch Med, Yokohama, Kanagawa, Japan
[5] Ofuna Chuo Hosp, Dept Radiol, Kamakura, Kanagawa, Japan
基金
日本学术振兴会;
关键词
stereotactic ablative body radiotherapy; SABR; locally advanced lung cancer; curative treatment; radical therapy; RADIATION-THERAPY; STAGE-I; ADJUVANT CHEMOTHERAPY; IMPROVED SURVIVAL; ARC; RESECTION; SURGERY; PROJECT; TUMOR; T3;
D O I
10.1093/jrr/rrz044
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The evidence for stereotactic body radiotherapy (SBRT) is meagre for patients with clinical T3-4N0M0 non-small cellung cancer (8th Edition of the Union for International Cancer Control (UICC)). This study retrospectively investigated clinical outcomes following SBRT for such patients. Among consecutive patients treated with SBRT, patients staged as cT3-4N0M0 by all criteria were examined, most of whom were unsuitable to chemoradiotherapy due to their fragile characters. Clinical outcomes were evaluated and factors associated with outcomes were investigated. Between 2005 and 2017, 70 eligible patients (T3: 58, T4: 12; median age 81 (63-93) years) were identified. Median follow-up duration was 28.6 (1.0-142.5) months. No adjuvant chemotherapy was administered. The 3-year local recurrence rates were 15.8% and 16.7% in T3 and T4 patients, respectively, and they were significantly lower in the high-dose group (3.1% vs 28.6%, P<0.01). Multivariate analyses showed that the dose-volumetric factor was the significant factor for local recurrence. The 3-year regional and distant metastasis rates, cancer-specific mortality, and overall survival in T3 and T4 patients were 22.7% and 25.0%, 26.5% and 33.3%, 32.2% and 41.7%, and 39.5% and 41.7%, respectively. Only age was correlated with overall survival. Radiation pneumonitis >= grade 3 and fatal hemoptysis occurred in 3 and 1 patients, respectively. SBRT for cT3-4N0M0 lung cancer patients achieved good local control. Survival was rather good considering that patients were usually frail, staged with clinical staging, and were not given adjuvant chemotherapy, and it may be comparable to surgery. To validate these outcomes following SBRT, a prospective study is warranted.
引用
收藏
页码:639 / 649
页数:11
相关论文
共 50 条
  • [21] Clinical Results of Stereotactic Body Radiation Therapy (SBRT) for Stage IB (T2aN0M0) Non-Small Cell Lung Cancer (NSCLC)
    Hashizume, C.
    Shibamoto, Y.
    Tsugawa, T.
    Otsuka, S.
    Hayashi, A.
    Takaoka, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E420 - E420
  • [22] Adjuvant chemotherapy for patients with T2N0M0 non-small cell lung cancer.
    Morgensztern, Daniel
    Waqar, Saiama Naheed
    Patel, Aalok
    Devarakonda, Siddhartha
    Waqar, Sadaf Huma
    Gao, Feng
    Robinson, Cliff Grant
    Bradley, Jeffrey D.
    Baggstrom, Maria Quintos
    Govindan, Ramaswamy
    Puri, Varun
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Patterns of failure and overall survival in patients with completely resected T3 no M0 non-small cell lung cancer
    Gould, PM
    Bonner, JA
    Sawyer, TE
    Deschamps, C
    Lange, CM
    Li, HZ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (01): : 91 - 95
  • [24] Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer
    Mihai, Alina
    Milano, Michael
    Santos, Ana
    Kennedy, Annemarie
    Thirion, Pierre
    McDermott, Ray S.
    Westrup, Jennifer
    Rock, Luke
    Armstrong, John
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (03) : 442 - 448
  • [25] The 8th UICC/AJCC TNM edition for non-small cell lung cancer staging: getting off to a flying start?
    Lancia, Andrea
    Merizzoli, Elisa
    Filippi, Andrea Riccardo
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [26] Stereotactic ablative radiotherapy for inoperable T1-2N0M0 small-cell lung cancer
    Tang, Hui
    Liu, Wei
    Huang, Kaiming
    THORACIC CANCER, 2022, 13 (07) : 1100 - 1101
  • [27] Survival Outcomes in Sublobar Resection for Clinical T1N0M0 Non-Small Cell Lung Cancer: Wedge Resection or Segmentectomy
    Kobayashi, Aki
    Ishikawa, Renta
    Takao, Motoshi
    Shimamoto, Akira
    Ito, Atsushi
    Shimpo, Hideto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S301 - S302
  • [28] Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer
    Kodama, Ken
    Higashiyama, Masahiko
    Okami, Jiro
    Tokunaga, Toshiteru
    Imamura, Fumio
    Nakayama, Tomio
    Inoue, Atsuo
    Kuriyama, Keiko
    ANNALS OF THORACIC SURGERY, 2016, 101 (02): : 504 - 511
  • [29] Definitive radiotherapy with or without chemotherapy for clinical stage T4N0-1 non-small cell lung cancer
    Kim, Yeon Joo
    Song, Si Yeol
    Jeong, Seong-Yun
    Kim, Sang We
    Lee, Jung-Shin
    Kim, Su Ssan
    Choi, Wonsik
    Choi, Eun Kyung
    RADIATION ONCOLOGY JOURNAL, 2015, 33 (04): : 284 - 293
  • [30] Patterns of Failure and Salvage Therapy in Stereotactic Body Radiotherapy for Stage I Non-small Cell Lung Cancer
    Taremi, M.
    Dahele, M.
    Purdie, T.
    Bissonnette, J.
    Fung, S.
    Brade, A.
    Cho, J.
    Hope, A.
    Sun, A.
    Bezjak, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S441 - S442